Summary#
This bill reauthorizes and extends parts of the Kay Hagan Tick Act that fund federal work on tick- and other vector-borne diseases. The main change is to move the authorization period for two programs from 2021–2025 to 2026–2030. It also replaces a specific reference to the “Tick-Borne Disease Working Group” with the more general phrase “appropriate individuals” in one advisory role.
- Main change: extends authorization of the National Strategy and Regional Centers of Excellence in Vector-Borne Disease and the Enhanced Support to Assist Health Departments program through 2030 instead of ending in 2025.
- Advisory change: removes the bill’s explicit reference to the Tick‑Borne Disease Working Group and replaces it with “appropriate individuals.”
- Policy goal (from title and text): continue federal programs that support research, coordination, and public-health work on tick-borne and other vector-borne diseases.
- What is unclear: the bill text does not state funding amounts, new activities, or how the advisory change will affect who provides guidance.
What it means for you#
- Public health agencies (federal, state, local): The federal authority for two programs that provide coordination, research support, regional centers, and assistance to health departments is extended for five years. This could allow continuing grants, training, surveillance, and technical help already provided under those programs.
- Regional research centers and universities: Centers that were funded or designated under the existing program may remain eligible for continued support while the authorization is in force.
- People at risk of tick-borne or other vector-borne diseases: The bill aims to keep federal programs running that support prevention, surveillance, and response efforts. This could mean continued public-health activities that detect and respond to illnesses transmitted by ticks or other vectors.
- Advisory groups and experts: The removal of the specific working group name means the law no longer requires that particular group to be the named advisor; instead the secretary must consult “appropriate individuals.” How that changes who gives advice is not specified.
- General public: If you interact with state or local health departments, you may see ongoing or renewed outreach, testing, or education efforts paid for by federal programs—if funding and grants continue in practice.
Expenses#
No publicly available information.
- The bill text does not list dollar amounts or include a fiscal note.
- It extends program authorizations but does not specify new funding levels, new fees, or budget offsets.
- Any actual federal spending, grant amounts, or administrative costs would depend on later appropriations (Congress deciding budget amounts).
- Potential costs to states or local health departments are not specified.
Proponents' View#
- The bill appears intended to keep federal programs that focus on tick-borne and other vector-borne diseases operating beyond 2025.
- Supporters may argue that extending authorization allows continued coordination, research, and regional support for prevention and response.
- The extension could be seen as helping health departments plan and sustain surveillance, diagnosis, and public education activities.
- Changing the advisory wording to “appropriate individuals” could be meant to allow more flexible or broader expert input.
Opponents' View#
- One concern is that the bill does not specify funding amounts, so it is unclear whether authorized programs will actually receive money or how much.
- Replacing the named Tick‑Borne Disease Working Group with “appropriate individuals” may reduce clarity about which experts must be consulted and could change continuity of advice; the practical effect is not explained.
- The bill gives little detail on oversight, performance measures, or how success will be judged over the extended period.
- Because no fiscal estimate is included in the text provided, it is hard to judge the budget trade-offs or the cost to taxpayers.